OTCMKTS:DNDNQ Dendreon (DNDNQ) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free DNDNQ Stock Alerts Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Dendreon alerts: Email Address Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Dendreon Stock (OTCMKTS:DNDNQ)Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company’s product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company’s product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.Read More Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide DNDNQ Stock News HeadlinesDecember 19, 2023 | bbc.comWho is House of Fraser's Yuan Yafei?October 21, 2023 | thestreet.comWhy Dendreon (DNDN) Stock Hit a One-Year Low TodayApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. September 27, 2023 | jp.reuters.comBB Biotech AGJuly 12, 2023 | thestreet.comThe Next Chapter in Dendreon's Troubled History: Chapter 11 BankruptcyJune 5, 2023 | thestreet.comDendreon Stock Hits New 52-Week Low (DNDN)April 22, 2023 | thestreet.comDendreon Stock Gaps Down On Today's Open (DNDN)February 23, 2023 | thestreet.comDendreon Will Run on Provenge OK: PollApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. February 10, 2023 | thestreet.comDendreon: Biotech Stock MailbagFebruary 7, 2023 | thestreet.comDendreon Readies Cost-Cutting PlanJanuary 14, 2023 | thestreet.comSAC Upped Dendreon Exposure Before BlowupSeptember 8, 2022 | thestreet.comDendreon, Ulta Beauty: After-Hours TradingSeptember 7, 2022 | thestreet.comDendreon Shares Roiled by Medicare QuestionsSeptember 6, 2022 | thestreet.comDendreon, Vion and Allos: Biotech MailbagFebruary 12, 2022 | thestreet.comJim Cramer Answers Questions on Dendreon, Salesforce and YelpSeptember 16, 2021 | prnewswire.comAeroSafe Global Appoints Rick Lozano as Chief Commercial Officer - PRNewswireSeptember 8, 2021 | bizjournals.comBolt Biotherapeutics, Bristol-Myers Squibb sign cancer immunotherapy deal - San Francisco Business Times - San Francisco Business TimesSeptember 7, 2021 | streetinsider.comImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives - StreetInsider.comSeptember 7, 2021 | finance.yahoo.comImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives - Yahoo FinanceSee More Headlines Receive DNDNQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dendreon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2014Today4/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorN/A Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:DNDNQ Previous SymbolNASDAQ:DNDN CUSIPN/A CIKN/A Webwww.dendreon.com Phone+1-206-2197815FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report DNDNQ Stock Analysis - Frequently Asked Questions How were Dendreon's earnings last quarter? Dendreon Corporation (OTCMKTS:DNDNQ) released its quarterly earnings data on Monday, November, 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biotechnology company had revenue of $73.10 million for the quarter, compared to analysts' expectations of $78.72 million. Dendreon's revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.44) EPS. How do I buy shares of Dendreon? Shares of DNDNQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DNDNQ) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dendreon Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
